---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-037819"
form_type: "8-K"
ticker: "RAPH"
cik: "0001415397"
company_name: "Raphael Pharmaceutical Inc."
filed_at: "2022-07-07T23:59:59+00:00"
generated_at: "2026-06-24T19:20:38.074397+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Raphael Pharma dismisses Deloitte auditor, Chairman Press resigns; new exec comp agreements

## Summary
- Dismissed Brightman Almagor Zohar (Deloitte) as auditor; appointed Weinstein International as new independent auditor.
- Chairman Prof. Joseph Press resigned from board effective June 30, 2022; consulting fee $1,000/meeting, 280k shares, 105k warrants at $1.12.
- CEO Shlomo Pilo (Sheffa Enterprises) gets new management agreement: $10k/mo (2022) then $20k/mo, 1M warrants at $1.12, expires Dec 2024.
- CFO Guy Ofir gets operations agreement: $6k/mo (2022) then $12k/mo, 1M restricted shares, 1M warrants at $1.00, expires Dec 2024.
- CTO Dr. Igal Louria Hayon: $9k/mo (2022) then $12k/mo, 990k warrants at $0.01, plus 15% of royalties from cannabis COVID and RA indications.

## SEC filing metadata
- accession: 0001213900-22-037819
- form_type: 8-K
- ticker: RAPH
- cik: 0001415397
- company_name: Raphael Pharmaceutical Inc.
- filed_at: 2022-07-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 4.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/0001213900-22-037819-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/ea162555-8k_raphael.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-037819
- JSON: https://secwatch.observer/filing/0001213900-22-037819.json
- Plain text: https://secwatch.observer/filing/0001213900-22-037819.txt

## Key facts
- Executive change
  Joseph Press resigned as Chairman of the Board of Directors at Raphael Pharmaceutical Inc..
  - Action: resigned
  - Role: Chairman of the Board of Directors
  source text: On June 30, 2022, Prof. Joseph Press informed the Company that he intended to resign from the Board of Directors, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1415397/000121390022037819/0001213900-22-037819-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.